NURECA

Nureca financials

Market cap
₹318 Cr
Sector
Healthcare

What Nureca Limited does

Nureca Limited is a digitally-native, D2C-first consumer healthcare company selling home diagnostics, wellness devices and personal fitness equipment under the Dr Trust and Dr Physio brands — spanning BP monitors, thermometers, electric massagers, weighing and kitchen scales, orthopedic pillows and supports, nebulizers/vaporizers/humidifiers, breast pumps and glucometers. It earns primarily through online sales (over 90% of revenue) via its own website, e-commerce marketplaces and quick-commerce platforms, supplemented by a growing offline distributor and retail network. Its wholly owned subsidiary, Nureca Technologies Pvt Ltd, manufactures several of these product categories in-house at a US FDA-registered facility in Mohali, Punjab. The company also runs Dr Trust 360, a freemium connected-health app that syncs its smart devices for tracking and AI-generated health insights.

Segments

  • Home Healthcare & Wellness Devices
  • In-house Manufacturing (Nureca Technologies Pvt Ltd)
  • Connected Health App (Dr Trust 360)
Active SKUs
305+
Installed manufacturing capacity
8 lakh units/year (India)
Offline distributor network
285+ distributors across 29 of 36 states/UTs
In-house manufacturing subsidiary
Nureca Technologies Pvt Ltd (Mohali, Punjab) — 10 product categories manufactured
Design patents
102
Regulatory approvals/certifications
15 CDSCO approvals; USFDA 510(k)-exempt clearance for 16 products; ISO 9001:2015 & ISO 13485:2016
Founded 2016Headquarters Mumbai, Maharashtra, IndiaEmployees 174 (FY25) Company website

Quarterly results

Q1 FY27: revenue up 18.0%, net profit up 279.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue31 26 32 34 38 +21%40 +50%35 +12%40 +18%
EBITDA-2 -4 1 -1 3 +239%3 +181%-6 −582%3 +711%
Net profit-0 -3 2 1 4 +856%4 +233%-6 −347%3 +279%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +30.8% 1Y

₹200₹250₹300₹350Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹254.3 on 10 Sept 2025 → ₹332.75. High ₹346.3 (14 Aug 2026), low ₹206.75 (30 Mar 2026).

Financials, as filed

Revenue grew 9.7% a year over 3 years, FY23 to FY26. Operating margin widened to 0.1%.

Year endingFY23FY24FY25FY26
Revenue₹111 Cr₹92 Cr₹110 Cr₹147 Cr
Operating profit₹-15 Cr₹-10 Cr₹-8 Cr₹0 Cr
Operating margin-13.5%-11.1%-6.9%0.1%
Interest₹0 Cr₹0 Cr₹1 Cr₹1 Cr
Depreciation₹2 Cr₹2 Cr₹2 Cr₹2 Cr
Net profit₹-8 Cr₹-2 Cr₹1 Cr₹2 Cr
Net margin-7.4%-2.0%0.8%1.4%
Cash from operations₹10 Cr₹-3 Cr₹-19 Cr₹3 Cr
Free cash flow₹10 Cr₹-4 Cr₹-23 Cr₹-3 Cr
ROCE-6.0%-4.0%1.0%3.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹10 Cr₹10 Cr₹10 Cr₹10 Cr₹10 Cr₹10 Cr
Reserves₹153 Cr₹193 Cr₹185 Cr₹183 Cr₹189 Cr₹171 Cr
Borrowings₹4 Cr₹4 Cr₹3 Cr₹3 Cr₹5 Cr₹2 Cr
Other liabilities₹19 Cr₹12 Cr₹8 Cr₹10 Cr₹21 Cr₹13 Cr
Total liabilities₹186 Cr₹219 Cr₹207 Cr₹205 Cr₹225 Cr₹196 Cr
Fixed assets₹4 Cr₹10 Cr₹9 Cr₹7 Cr₹14 Cr₹14 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹0 Cr₹33 Cr₹59 Cr₹94 Cr₹8 Cr₹1 Cr
Other assets₹182 Cr₹175 Cr₹139 Cr₹104 Cr₹203 Cr₹182 Cr
Total assets₹186 Cr₹219 Cr₹207 Cr₹205 Cr₹225 Cr₹196 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public trimmed −3.99 pp while promoters added +3.76 pp. The shareholder count shrank 11% to 33,979.

Promoters
68.1%
FIIs
0.1%
DIIs
0.2%
Public
31.6%

Since Jun 2025

  • Public −3.99 pp
  • Promoters +3.76 pp
  • DIIs +0.20 pp

How it drifted, 12 quarters

Over this window the public fell from 36.7% to 31.6% — −5.1 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 63.2%, FIIs 0.1%, Public 36.7%.Dec '23: Promoters 63.2%, FIIs 0.1%, Public 36.7%.Mar '24: Promoters 63.2%, FIIs 0.1%, Public 36.7%.Jun '24: Promoters 63.2%, FIIs 0.1%, Public 36.7%.Sep '24: Promoters 63.8%, FIIs 0.7%, Public 35.5%.Dec '24: Promoters 64.1%, FIIs 0.4%, DIIs 0.0%, Public 35.5%.Mar '25: Promoters 64.3%, FIIs 1.1%, DIIs 0.0%, Public 34.6%.Jun '25: Promoters 64.3%, FIIs 0.1%, DIIs 0.0%, Public 35.6%.Sep '25: Promoters 65.0%, FIIs 0.1%, DIIs 0.0%, Public 34.9%.Dec '25: Promoters 65.0%, FIIs 0.1%, DIIs 0.0%, Public 34.9%.Mar '26: Promoters 68.1%, FIIs 0.3%, DIIs 0.2%, Public 31.4%.Jun '26: Promoters 68.1%, FIIs 0.1%, DIIs 0.2%, Public 31.6%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Nureca Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Saurabh Goyal 34.35%+0.63 pp
Payal Goyal 21.59%unchanged
Aryan Goyal 12.15%unchanged
Nectar Biopharma Private Limited 0.00%−0.64 pp
Smita Goyal 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Nureca Limited

Guides on how to read this kind of business and the numbers that matter.